HRP20240195T8 - Antitijela na lif i njihove primjene - Google Patents

Antitijela na lif i njihove primjene Download PDF

Info

Publication number
HRP20240195T8
HRP20240195T8 HRP20240195TT HRP20240195T HRP20240195T8 HR P20240195 T8 HRP20240195 T8 HR P20240195T8 HR P20240195T T HRP20240195T T HR P20240195TT HR P20240195 T HRP20240195 T HR P20240195T HR P20240195 T8 HRP20240195 T8 HR P20240195T8
Authority
HR
Croatia
Prior art keywords
lif
antibodies
applications
Prior art date
Application number
HRP20240195TT
Other languages
English (en)
Croatian (hr)
Inventor
Joan Seoane Suarez
Judit Anido Folgueira
Johan Fransson
Jean-Philippe Julien
Swetha RAMAN
Original Assignee
Medimmune Limited
Fundació Privada Institució Catalana De Recerca I Estudis Avançats
Fundació Privada Institut D'investigació Oncològica De Vall-Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Limited, Fundació Privada Institució Catalana De Recerca I Estudis Avançats, Fundació Privada Institut D'investigació Oncològica De Vall-Hebron filed Critical Medimmune Limited
Priority claimed from PCT/IB2017/001677 external-priority patent/WO2018115960A1/en
Publication of HRP20240195T1 publication Critical patent/HRP20240195T1/hr
Publication of HRP20240195T8 publication Critical patent/HRP20240195T8/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20240195TT 2016-12-19 2017-12-18 Antitijela na lif i njihove primjene HRP20240195T8 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16382617 2016-12-19
US201762467017P 2017-03-03 2017-03-03
EP17382683 2017-10-13
PCT/IB2017/001677 WO2018115960A1 (en) 2016-12-19 2017-12-18 Antibodies against lif and uses thereof
EP17840489.3A EP3555132B1 (en) 2016-12-19 2017-12-18 Antibodies against lif and uses thereof

Publications (2)

Publication Number Publication Date
HRP20240195T1 HRP20240195T1 (hr) 2024-04-26
HRP20240195T8 true HRP20240195T8 (hr) 2024-05-24

Family

ID=67138942

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240195TT HRP20240195T8 (hr) 2016-12-19 2017-12-18 Antitijela na lif i njihove primjene

Country Status (24)

Country Link
US (2) US11390670B2 (enExample)
EP (2) EP4321219A3 (enExample)
JP (3) JP7100056B2 (enExample)
KR (3) KR102599557B1 (enExample)
CN (2) CN111868086B (enExample)
AU (1) AU2017381585B2 (enExample)
BR (1) BR112019012691A2 (enExample)
CA (1) CA3047528A1 (enExample)
CL (2) CL2019001717A1 (enExample)
DK (1) DK3555132T3 (enExample)
ES (1) ES2971126T3 (enExample)
FI (1) FI3555132T3 (enExample)
HR (1) HRP20240195T8 (enExample)
HU (1) HUE065241T2 (enExample)
IL (2) IL267450B (enExample)
LT (1) LT3555132T (enExample)
MX (2) MX2019007376A (enExample)
NZ (1) NZ755004A (enExample)
PL (1) PL3555132T3 (enExample)
RS (1) RS65187B1 (enExample)
SA (1) SA519402119B1 (enExample)
SI (1) SI3555132T1 (enExample)
SM (1) SMT202400065T1 (enExample)
ZA (1) ZA201904533B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3555132T (lt) * 2016-12-19 2024-02-26 Medimmune Limited Antikūnai prieš lif ir jų panaudojimas
SG11202009966SA (en) * 2018-04-12 2020-11-27 Medimmune Ltd Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
EP4069736A1 (en) * 2019-12-04 2022-10-12 MedImmune Limited Antibodies against lif and uses thereof
TWI841810B (zh) 2020-01-24 2024-05-11 日商西斯美股份有限公司 提升抗體對抗原之親和性的方法及其用途
CN117043189A (zh) 2020-12-31 2023-11-10 诺纳生物（苏州）有限公司 人lifr抗原结合蛋白及其制备方法和应用
TW202306993A (zh) * 2021-05-14 2023-02-16 美商建南德克公司 Ｔｒｅｍ２之促效劑

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
AU4231393A (en) 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
AU4241693A (en) 1992-05-15 1993-12-13 Re/Map Incorporated Electromagnetic shielding for a liquid conditioning device
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
EP1287832B1 (en) 1995-04-24 2005-12-21 Genentech, Inc. Use of leukemia inhibitory factor antagonist
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003085093A2 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1612558A1 (en) 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
AP2007004243A0 (en) 2005-04-25 2007-12-31 Pfizer Antibodies to myostatin
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
EP2084185A4 (en) 2006-10-04 2010-11-17 Scripps Research Inst HUMAN ANTIBODIES THAT NEUTRALIZE HUMAN METAPNEUMOVIRUS
CN101440128A (zh) 2007-11-21 2009-05-27 中国人民解放军第二军医大学 人脑胶质瘤中差异表达的蛋白及其用途
CA2742969A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
WO2011057144A2 (en) 2009-11-06 2011-05-12 La Jolla Institute For Allergy And Immunology Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
IL275376B2 (en) 2013-03-11 2024-01-01 Genzyme Corp Hyperglycosylated binding polypeptides
US20140314741A1 (en) 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
US10633429B2 (en) 2013-08-20 2020-04-28 Japan Science And Technology Agency Human antibody κ type light chain complex-containing composition and method for producing same
US20150056195A1 (en) 2013-08-23 2015-02-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy
US20160237158A1 (en) 2013-09-23 2016-08-18 Institut National De La Santé Et Da La Recherche Médicale (Inserm) Methods and Compositions for Targeting Tumor Microenvironment and for preventing Metastasis
JP6496719B2 (ja) 2013-10-09 2019-04-03 リサーチ ディベロップメント ファウンデーション モノクローナルｏｌｆｍｌ−３抗体及びその使用
TWI486172B (zh) 2013-11-08 2015-06-01 Univ Chang Gung 鼻咽癌治療的醫藥
WO2015106080A2 (en) 2014-01-10 2015-07-16 Anaptysbio, Inc. Antibodies directed against interleukin-33 (il-33)
EP4640239A2 (en) 2014-03-19 2025-10-29 Genzyme Corporation Site-specific glycoengineering of targeting moieties
WO2016040657A1 (en) 2014-09-10 2016-03-17 The Regents Of The University Of California TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
LT3555132T (lt) * 2016-12-19 2024-02-26 Medimmune Limited Antikūnai prieš lif ir jų panaudojimas
SG11202009966SA (en) * 2018-04-12 2020-11-27 Medimmune Ltd Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
KR20210024007A (ko) * 2018-06-18 2021-03-04 메디뮨 리미티드 암이 있는 개체에서 항-lif 항체 치료에 대한 반응을 개선하기 위한 방법

Also Published As

Publication number Publication date
IL267450A (en) 2019-08-29
SI3555132T1 (sl) 2024-04-30
EP4321219A2 (en) 2024-02-14
SMT202400065T1 (it) 2024-03-13
KR102716931B1 (ko) 2024-10-15
HRP20240195T1 (hr) 2024-04-26
JP2020512388A (ja) 2020-04-23
NZ755004A (en) 2025-08-29
JP2022130632A (ja) 2022-09-06
CN111868086A (zh) 2020-10-30
CL2019001717A1 (es) 2020-02-28
DK3555132T3 (da) 2024-02-05
CL2021000950A1 (es) 2021-11-26
CA3047528A1 (en) 2018-06-28
EP4321219A3 (en) 2024-05-15
EP3555132A1 (en) 2019-10-23
KR20230125099A (ko) 2023-08-28
CN111868086B (zh) 2024-07-16
JP7100056B2 (ja) 2022-07-12
IL294088B2 (en) 2023-10-01
US11390670B2 (en) 2022-07-19
ZA201904533B (en) 2024-08-28
IL267450B (en) 2022-07-01
SA519402119B1 (ar) 2023-02-19
JP7459173B2 (ja) 2024-04-01
MX2024003178A (es) 2024-03-25
PL3555132T3 (pl) 2024-04-22
KR20240149987A (ko) 2024-10-15
HUE065241T2 (hu) 2024-05-28
IL294088B1 (en) 2023-06-01
BR112019012691A2 (pt) 2019-11-19
AU2017381585B2 (en) 2025-02-13
KR102784394B1 (ko) 2025-03-19
AU2017381585A1 (en) 2019-07-18
US20230042095A1 (en) 2023-02-09
ES2971126T3 (es) 2024-06-03
RS65187B1 (sr) 2024-03-29
IL294088A (en) 2022-08-01
KR102599557B1 (ko) 2023-11-07
JP2024075682A (ja) 2024-06-04
LT3555132T (lt) 2024-02-26
US20190352389A1 (en) 2019-11-21
MX2019007376A (es) 2020-02-07
EP3555132B1 (en) 2023-11-15
CN118652335A (zh) 2024-09-17
KR20190122652A (ko) 2019-10-30
FI3555132T3 (fi) 2024-02-08

Similar Documents

Publication Publication Date Title
IL271110A (en) Antibodies specific for flt3 and their uses
KR102355950B9 (ko) Tigit에 대한 항체
IL262095A (en) Anti-pacap antibodies and uses thereof
IL258088A (en) Il-8-binding antibodies and uses thereof
PL3423105T3 (pl) Koniugaty przeciwciało-lek oparte na erybulinie i sposoby zastosowania
PL3443009T3 (pl) Przeciwciała i kompozycje anty-tim-3
EP3498840A4 (en) ANTI-LAG-3 ANTIBODIES
EP3481869A4 (en) ANTI-CD73 ANTIBODIES
HUE055331T2 (hu) Pro/látens-miosztatin elleni ellenanyagok és alkalmazásuk
DK3333192T3 (da) Antistof imod glypican-3 og anvendelse deraf
HUE056337T2 (hu) Biológiai szerek és alkalmazásuk növényeknél
DK3280728T3 (da) Alk7:actriib-heteromultimerer og anvendelser deraf
HUE045307T2 (hu) EGFRVIII-ellenes antitestek és alkalmazásaik
DK3274370T3 (da) Anti-ceacam6-antistoffer og anvendelser deraf
LT3280441T (lt) Anti-sortilino antikūnai ir jų naudojimo būdai
PT3354729T (pt) Anticorpo anti-garp
LT3258951T (lt) Anti-pvrig antikūnai ir jų panaudojimo būdai
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
DK2970460T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
LT3532499T (lt) Antikūnai prieš il-33 ir jų panaudojimas
IL263273A (en) Anti-gitr antibodies and uses thereof
DK3463435T3 (da) Alpha-synuklein-antistoffer og anvendelser deraf
IL256099A (en) Antibody
PL3402821T3 (pl) Przeciwciało wiążące psma i jego zastosowania
HRP20240195T8 (hr) Antitijela na lif i njihove primjene